ReviewCancers2023
Susceptibility Genes Associated with Multiple Primary Cancers.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Impact of TP53 somatic mutations on prognosis in endometrial cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional/prospective study design (FAHIC: lung).Journal of translational medicine · 2024Pooled it
- Familial Risk Stratification Across Cancer Syndromes Using Fam3PRO.Genetics in medicine : official journal of the American College of Medical Genetics · 2026Article
- Integrated Clinicogenomic Risk Modeling for Metachronous Second Primary Cancers.medRxiv : the preprint server for health sciences · 2026Article
- Immunohistochemical characterization of the tumor immune microenvironment in laryngeal premalignancy: insights into early immune alterations in carcinogenesis.Virchows Archiv : an international journal of pathology · 2026Article
- Expression of Estrogen Receptor Alpha and Ki-67 in Synchronous Canine Mammary Tumors.Journal of mammary gland biology and neoplasia · 2026Article
- Evaluating a Mendelian Risk Prediction Model That Aggregates Across Genes and Cancers.Genetic epidemiology · 2026Article
- Article
- A case report of synchronous bilateral breast cancer with distinct histological subtypes and favorable long-term survival.Frontiers in oncology · 2026Article
- Synchronous Breast and Kidney Carcinomas Following Treatment for Hodgkin's Lymphoma in Young Adulthood: A Case Report and Literature Review.Journal of clinical medicine · 2025Article
- The value of [BMC medical imaging · 2025Article
- Endometrial Carcinoma and Associated Secondary Neoplasia: The Role of Clinical Features, Pathology, and Comorbidities in a University-Affiliated Clinical Center from Western Romania.Medicina (Kaunas, Lithuania) · 2025Article
- Article
- Three Different Primary Cancers, Including Breast, Esophagus, and Renal in a Single Patient: A Case Report.Clinical case reports · 2025Article
- Recent advances in the methods and clinical applications of next-generation sequencing in genomic profiling and precision cancer therapy.EXCLI journal · 2025Review
- Coexistence of low-grade pulmonary mucinous epithelioid carcinoma and metastatic adrenal sarcomatoid carcinoma: a rare case report with BRAF p.V600E-driven molecular insights and clinical challenges.Frontiers in oncology · 2025Article
- Synchronous Seminoma of Testis and Renal Cell Carcinoma: A Rare Case Report.Medicina (Kaunas, Lithuania) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
With advancements in treatment and screening techniques, we have been witnessing an era where more cancer survivors harbor multiple primary cancers (MPCs), affecting approximately one in six patients. Identifying MPCs is crucial for tumor staging and subsequent treatment choices. However, the current clinicopathological criteria for clinical application are limited and insufficient, making it challenging to differentiate them from recurrences or metastases. The emergence of next-generation sequencing (NGS) technology has provided a genetic perspective for defining multiple primary cancers. Researchers have found that, when considering multiple tumor pairs, it is crucial not only to examine well-known essential mutations like MLH1/MSH2, EGFR, PTEN, BRCA1/2, CHEK2, and TP53 mutations but also to explore certain pleiotropic loci. Moreover, specific deleterious mutations may serve as regulatory factors in second cancer development following treatment. This review aims to discuss these susceptibility genes and provide an explanation of their functions based on the signaling pathway background. Additionally, the association network between genetic signatures and different tumor pairs will be summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.